Amgen is one of the world's largest independent biotechnology companies, developing medicines in oncology, cardiovascular disease, inflammation, bone health, neuroscience, and rare disease. Amgen's portfolio includes biologics like Repatha, Prolia/Xgeva, Otezla, Enbrel (ex-North America), Aranesp, Neulasta, and the recent Horizon Therapeutics acquisition adding Tepezza, Krystexxa, and Ubrelvy.
Amgen eliminated approximately 40 positions amid commercial and regulatory headwinds surrounding Tavneos and targeted pipeline reprioritization.
With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation.
Amgen hit with FDA warning letter for ‘misleading’ video
Amgen reveals 6-point drop in lupus severity behind ph. 2 win
An investigational drug for the autoimmune condition Sjogren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.
Amgen’s Imdelltra scores overall survival win in first-line SCLC
Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds
Amgen, AZ's Tezspire lands ph. 3 eosinophilic esophagitis win
Amgen, medical centers diverge on potential conflicts in FDA pilot to speed early drug trials
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
Amgen discontinued an early-stage obesity candidate, leaving MariTide as its lead obesity asset while analysts push for more M&A.
Amgen sees continued momentum for its cholesterol drug Repatha, expecting the cardiology product's sales growth to keep rolling.
Amgen reports hackers stole company and patient information in a data breach, noticing unauthorized activity affecting data stored on cloud platforms hosted by third-party providers in July.
Amgen has submitted new analyses to the FDA in a bid to retain marketing authorization for Tavneos (avacopan) following agency concerns about the rare-disease drug's real-world performance.
Amgen has cut approximately 40 positions as the company faces pipeline setbacks and competitive pressure on key products including Tavneos.
Amgen has submitted a data package to FDA in a bid to secure a hearing over the agency's recent rejection of Tavneos for a label expansion.
Amgen agreed to pay $74 million to resolve an investor lawsuit over a $107 billion tax bill.
NICE aims to cut funding for Amgen lung cancer drug Lumykras Lumykras, which is known as Lumakras in some markets, will no longer be covered by the Cancer Drugs Fund, according to the health technology assessment (HTA) agency. Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in England and Wales, saying the decision does not reflect experience with the lung cancer therapy since it was first made available four years ago.
Amgen recalls almost 1 million bottles of heart failure drug over quality issue (reported by BioSpace)
Court halts Colorado price cap on Amgen's blockbuster Enbrel — Endpoints News coverage of biopharma industry developments.
NEJM retracts pivotal data for Amgen's Tavneos — Endpoints News coverage of biopharma industry developments.
Amgen CFO Transition as Peter Griffith Retires, Thomas Dittrich Returns.
Viridian may have edge over Amgen in eye drug showdown, analysts argue. (BioPharma Dive.)
An Important Update Regarding TAVNEOS (avacopan).
CEO